Empowered Funds LLC Acquires Shares of 190,586 Sarepta Therapeutics, Inc. $SRPT

Empowered Funds LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 190,586 shares of the biotechnology company’s stock, valued at approximately $3,425,000. Empowered Funds LLC owned about 0.18% of Sarepta Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 636 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares during the period. Larson Financial Group LLC grew its stake in shares of Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 851 shares during the period. Finally, Public Employees Retirement System of Ohio increased its holdings in shares of Sarepta Therapeutics by 3.1% during the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 875 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Up 1.4%

SRPT stock opened at $21.33 on Wednesday. Sarepta Therapeutics, Inc. has a 52 week low of $14.68 and a 52 week high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The firm has a 50-day simple moving average of $17.88 and a 200-day simple moving average of $18.36. The stock has a market capitalization of $2.25 billion, a P/E ratio of -7.36, a P/E/G ratio of 0.31 and a beta of 0.26.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The company had revenue of $401.25 million for the quarter, compared to analysts’ expectations of $366.39 million. During the same period in the previous year, the firm posted $2.02 EPS. Sarepta Therapeutics’s revenue was down 34.3% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Wall Street Zen lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, July 9th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Finally, Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $25.06.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.